Figure 3.

Different GlcNAc concentrations in DV CaPNP/multipeptide formulations stimulate CD8+ T cell activation in vivo. Following the protocol in Fig 1A, CTL responses were generated with the following groups in HLA-A2⁺ transgenic mice: Group1) unimmunized (PBS control); Group 2) 10µg peptide/150µL PBS per mouse emulsified in ISA 51; Group 3) 10µg peptide/150µl CaPNP per mouse; Group 4) 10µg peptide/150µl CaPNP with 1XGlcNAc per mouse; Group 5) 10µg peptide/150µl CaPNP with 3XGlcNAc per mouse. Splenocytes were harvested and co-cultured with HepG2 targets that were pulsed with either no peptides (negative control), or pooled free peptides (NIQ, TIT, VTL, KLA, AML, LLC) or infected with DV2 for use in the ELISpot assay. Data represented as mean ± S.D (n = 3) of SFU per 1 million splenocytes. * Represents P values: * P<0.05, ** P<0.01, ***P<0.001, **** P<0.0001.